Literature DB >> 29755645

Hepatic steatosis in chronic hepatitis B: a study of metabolic and genetic factors.

Michael O Baclig1, Karen G Reyes1, Veni R Liles1, Cynthia A Mapua1, Mark Pierre S Dimamay1, Juliet Gopez-Cervantes2.   

Abstract

Hepatic steatosis is a common finding in liver biopsy and may co-exist with chronic hepatitis B (CHB) infection. The aims of this study were to determine the prevalence of steatosis in CHB patients among Filipinos; determine the factors related to the presence of steatosis among individuals with and without CHB infection; and to investigate the possible association between steatosis and polymorphism in interleukin 28B (IL28B) gene. The presence of steatosis was correlated with clinical, biochemical and histological parameters. Peripheral blood samples of CHB patients with steatosis, CHB patients without steatosis and normal controls were genotyped for IL28B rs8099917 T>G using the TaqMan assay. Of the 46 CHB patients, 41% (19/46) had steatosis. Body mass index (BMI), fasting blood sugar (FBS), lipid profile and alanine transaminase levels were observed to be significantly different between CHB patients with steatosis and normal controls. The serum FBS of CHB patients with steatosis was significantly higher than patients without steatosis. High density lipoprotein cholesterol of patients without steatosis was significantly higher than patients with steatosis. Although not statistically significant, BMI, triglycerides, low density lipoprotein cholesterol and histology activity index in CHB patients with steatosis were found to be higher than those without steatosis. There was no significant association between the stage of fibrosis and severity of steatosis. In conclusion, the prevalence of hepatic steatosis among Filipino patients with CHB is 41%. Steatosis in CHB patients was associated with metabolic factors such as diabetes and dyslipidemia. IL28B rs8099917 T>G polymorphism is not associated with steatosis.

Entities:  

Keywords:  Chronic hepatitis B; hepatic steatosis; interferon λ; interleukin 28B rs8099917; metabolic factors; polymorphism

Year:  2018        PMID: 29755645      PMCID: PMC5944810     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  28 in total

1.  IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.

Authors:  Salvatore Petta; Stefania Grimaudo; Calogero Cammà; Daniela Cabibi; Vito Di Marco; Giusalba Licata; Rosaria Maria Pipitone; Antonio Craxì
Journal:  J Hepatol       Date:  2012-02-05       Impact factor: 25.083

2.  Multi-SNP Haplotype Analysis Methods for Association Analysis.

Authors:  Daniel O Stram
Journal:  Methods Mol Biol       Date:  2017

3.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

4.  Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

Authors:  Raluca Pais; Elena Rusu; Diana Zilisteanu; Alexandra Circiumaru; Laurentiu Micu; Mihai Voiculescu; Thierry Poynard; Vlad Ratziu
Journal:  Eur J Intern Med       Date:  2014-12-29       Impact factor: 4.487

5.  Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection.

Authors:  Jun-ping Shi; Jian-gao Fan; Rui Wu; Xiao-qian Gao; Li Zhang; Hao Wang; Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2008-09       Impact factor: 4.029

6.  The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III.

Authors:  Sung-Koo Kang; Tae-Wook Chung; Ji-Young Lee; Young-Choon Lee; Richard E Morton; Cheorl-Ho Kim
Journal:  J Biol Chem       Date:  2004-04-29       Impact factor: 5.157

7.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors.

Authors:  Man-Man Wang; Gong-Sui Wang; Feng Shen; Guang-Yu Chen; Qin Pan; Jian-Gao Fan
Journal:  Dig Dis Sci       Date:  2014-05-18       Impact factor: 3.199

9.  Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease.

Authors:  José A Agúndez; Elena García-Martin; María L Maestro; Francisca Cuenca; Carmen Martínez; Luis Ortega; Miguel Carballo; Marta Vidaurreta; Marta Agreda; Gabriela Díaz-Zelaya; Avelina Suárez; Manuel Díaz-Rubio; José M Ladero
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

10.  Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.

Authors:  Masaya Sato; Mayuko Kondo; Ryosuke Tateishi; Naoto Fujiwara; Naoya Kato; Haruhiko Yoshida; Masataka Taguri; Kazuhiko Koike
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

View more
  1 in total

1.  Reproducibility of ultrasound attenuation imaging for the noninvasive evaluation of hepatic steatosis.

Authors:  Jeongin Yoo; Jeong Min Lee; Ijin Joo; Dong Ho Lee; Jeong Hee Yoon; Hyo-Jin Kang; Su Joa Ahn
Journal:  Ultrasonography       Date:  2019-08-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.